In June 2025, the Indian Ministry of Health and Family Welfare introduced new guidelines aimed at enhancing the quality standards for pharmaceutical exports. These guidelines emphasize stricter compliance with Good Manufacturing Practices (GMP) to ensure the safety and efficacy of exported medicines.
In September 2025, the World Health Organization (WHO) updated its Model List of Essential Medicines, adding several new treatments for non-communicable diseases. While "Gutika" was not included in this update, the revision reflects the WHO's ongoing efforts to address global health challenges.
In December 2025, the European Medicines Agency (EMA) implemented revised guidelines for the assessment of herbal medicinal products. These guidelines aim to streamline the approval process for herbal medicines, potentially impacting products like "Gutika" seeking entry into the European market.
In February 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance document outlining the regulatory framework for combination products that include both drug and device components. This guidance provides clarity on the approval process for such products, which may be relevant for complex formulations similar to "Gutika."
In March 2026, the Indian government announced a reduction in export duties for certain pharmaceutical products to boost international trade. This policy change is expected to benefit exporters of "Gutika" by making the product more competitive in global markets.
